Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1304) 1304
humans (1021) 1021
female (718) 718
bridged-ring compounds - therapeutic use (606) 606
middle aged (457) 457
animals (447) 447
oncology (447) 447
male (420) 420
adult (387) 387
aged (379) 379
bridged-ring compounds - administration & dosage (375) 375
antineoplastic combined chemotherapy protocols - therapeutic use (362) 362
breast neoplasms - drug therapy (324) 324
bridged-ring compounds - pharmacology (318) 318
taxoids - therapeutic use (288) 288
taxoids - administration & dosage (275) 275
chemotherapy (272) 272
cancer (234) 234
pharmacology & pharmacy (232) 232
antineoplastic agents - therapeutic use (230) 230
treatment outcome (222) 222
mice (211) 211
breast cancer (198) 198
breast neoplasms - pathology (191) 191
paclitaxel (182) 182
rats (181) 181
taxoids (144) 144
docetaxel (134) 134
retrospective studies (128) 128
disease-free survival (121) 121
neoplasm staging (120) 120
bridged-ring compounds - chemistry (117) 117
prognosis (115) 115
bridged-ring compounds - adverse effects (114) 114
aged, 80 and over (113) 113
analysis (112) 112
drug resistance, neoplasm (107) 107
chemotherapy, adjuvant (106) 106
care and treatment (105) 105
therapy (105) 105
dose-response relationship, drug (103) 103
survival (102) 102
bridged bicyclo compounds - therapeutic use (101) 101
deoxycytidine - analogs & derivatives (98) 98
monoterpenes (98) 98
taxane (97) 97
research (95) 95
carcinoma (93) 93
anthracyclines - administration & dosage (92) 92
anthracyclines - therapeutic use (91) 91
ovarian neoplasms - drug therapy (89) 89
clinical trials as topic (88) 88
medicine & public health (88) 88
neoadjuvant therapy (87) 87
taxoids - adverse effects (86) 86
survival rate (83) 83
antineoplastic combined chemotherapy protocols - adverse effects (82) 82
time factors (82) 82
trial (82) 82
hematology, oncology and palliative medicine (79) 79
neoplasm metastasis (78) 78
cell line, tumor (74) 74
chemistry, medicinal (73) 73
drug administration schedule (73) 73
paeoniflorin (72) 72
abridged index medicus (70) 70
antineoplastic agents - pharmacology (70) 70
deoxycytidine - administration & dosage (70) 70
taxoids - pharmacology (69) 69
apoptosis (68) 68
expression (68) 68
lung neoplasms - drug therapy (68) 68
cisplatin (66) 66
survival analysis (66) 66
breast neoplasms - mortality (65) 65
anthracyclines (63) 63
health aspects (63) 63
antineoplastic agents - adverse effects (62) 62
article (62) 62
obstetrics & gynecology (62) 62
rats, sprague-dawley (62) 62
breast neoplasms - metabolism (61) 61
cisplatin - administration & dosage (61) 61
fluorouracil - administration & dosage (61) 61
follow-up studies (60) 60
metastasis (60) 60
ovarian cancer (60) 60
taxanes (60) 60
ramipril (57) 57
carcinoma, non-small-cell lung - drug therapy (56) 56
trastuzumab (56) 56
biochemistry & molecular biology (55) 55
receptor, erbb-2 - metabolism (55) 55
administration, oral (54) 54
cells (54) 54
adjuvant chemotherapy (53) 53
apoptosis - drug effects (53) 53
glucosides - pharmacology (53) 53
neoadjuvant chemotherapy (53) 53
antineoplastic agents - administration & dosage (51) 51
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1243) 1243
Japanese (39) 39
Russian (25) 25
Chinese (21) 21
German (14) 14
Italian (14) 14
French (12) 12
Spanish (3) 3
Bulgarian (1) 1
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
by Untch, Michael, Prof|Loibl, Sibylle, MD|Bischoff, Joachim, MD|Eidtmann, Holger, MD|Kaufmann, Manfred, Prof|Blohmer, Jens-Uwe, Prof|Hilfrich, Jörn, Prof|Strumberg, Dirk, Prof|Fasching, Peter A, Prof|Kreienberg, Rolf, Prof|Tesch, Hans, Prof|Hanusch, Claus, MD|Gerber, Bernd, Prof|Rezai, Mahdi, MD|Jackisch, Christian, Prof|Huober, Jens, Prof|Kühn, Thorsten, Prof|Nekljudova, Valentina, PhD|von Minckwitz, Gunter, Prof and Arbeitsgemeinschaft Gynaekologisch and German Breast Grp GBG and Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group and German Breast Group (GBG)
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 2, pp. 135 - 144
Summary Background We compared the efficacy and safety of the addition of lapatinib versus trastuzumab to anthracycline-taxane-based neoadjuvant chemotherapy.... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | WOMEN | EPIRUBICIN | THERAPY | EFFICACY | ONCOLOGY | SAFETY | CYCLOPHOSPHAMIDE | METASTATIC BREAST-CANCER | PLUS | PACLITAXEL | Antibodies, Monoclonal, Humanized - adverse effects | Breast Neoplasms - surgery | Bridged-Ring Compounds - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols | Breast Neoplasms - drug therapy | Young Adult | Taxoids - therapeutic use | Breast Neoplasms - pathology | Quinazolines - therapeutic use | Quinazolines - adverse effects | Female | Neoadjuvant Therapy | Aged | Anthracyclines - therapeutic use | Neoplasm Staging | Trastuzumab | Antimitotic agents | Chemotherapy | Product development | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
by Linda T. Vahdat and Brian Pruitt and Carol J. Fabian and Ragene R. Rivera and David A. Smith and Elizabeth Tan-Chiu and Jonathan Wright and Antoinette R. Tan and Noshir A. DaCosta and Ellen Chuang and John Smith and Joyce O'Shaughnessy and Dale E. Shuster and Nicole L. Meneses and Kumari Chandrawansa and Fang Fang and Patricia E. Cole and Simon Ashworth and Joanne L. Blum
Journal of Clinical Oncology, ISSN 0732-183X, 06/2009, Volume 27, Issue 18, pp. 2954 - 2961
Purpose Eribulin mesylate (E7389), a nontaxane microtubule dynamics inhibitor, is a structurally simplified, synthetic analog of the marine natural product... 
CAPECITABINE | IXABEPILONE BMS-247550 | CLINICAL-TRIAL | SOLID TUMORS | E7389 | VINORELBINE | ONCOLOGY | 1ST-LINE THERAPY | CHEMOTHERAPY | GEMCITABINE | PACLITAXEL | Bridged-Ring Compounds - therapeutic use | Macrolides | Humans | Middle Aged | Ketones - administration & dosage | Treatment Outcome | Antineoplastic Agents - therapeutic use | Breast Neoplasms - drug therapy | Furans - therapeutic use | Ketones - toxicity | Taxoids - therapeutic use | Neoplasm Metastasis | Microtubules - drug effects | Aged, 80 and over | Ethers, Cyclic - therapeutic use | Adult | Female | Aged | Ketones - therapeutic use | Anthracyclines - therapeutic use | Furans - toxicity | Furans - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial
by Perez, Edith A, Dr|Awada, Ahmad, MD|O'Shaughnessy, Joyce, MD|Rugo, Hope S, MD|Twelves, Chris, MD|Im, Seock-Ah, MD|Gómez-Pardo, Patricia, MD|Schwartzberg, Lee S, MD|Diéras, Veronique, MD|Yardley, Denise A, MD|Potter, David A, MD|Mailliez, Audrey, MD|Moreno-Aspitia, Alvaro, MD|Ahn, Jin-Seok, MD|Zhao, Carol, MS|Hoch, Ute, PhD|Tagliaferri, Mary, MD|Hannah, Alison L, MD|Cortes, Javier, MD
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 15, pp. 1556 - 1568
Summary Background New options are needed for patients with heavily pretreated breast cancer. Etirinotecan pegol is a long-acting topoisomerase-I inhibitor... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | RESISTANT | IXABEPILONE PLUS CAPECITABINE | PHARMACOKINETICS | ONCOLOGY | Bridged-Ring Compounds - therapeutic use | Physicians | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Antibiotics, Antineoplastic | Capecitabine - therapeutic use | Breast Neoplasms - drug therapy | Polyethylene Glycols - therapeutic use | Taxoids - therapeutic use | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Breast Neoplasms - pathology | Aged, 80 and over | Adult | Female | Aged | Anthracyclines - therapeutic use | Neoplasm Staging | Medical colleges | Care and treatment | Anthracyclines | Breast cancer | Product development | Metabolites | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
by Thuss-Patience, Peter C, MD|Shah, Manish A, MD|Ohtsu, Atsushi, MD|Van Cutsem, Eric, Prof|Ajani, Jaffer A, Prof|Castro, Hugo, MD|Mansoor, Wasat, PhD|Chung, Hyun Cheol, Prof|Bodoky, Gyorgy, Prof|Shitara, Kohei, MD|Phillips, Gail D Lewis, MS|van der Horst, Tina, MSc|Harle-Yge, Marie-Laurence, MSc|Althaus, Betsy L, PharmD|Kang, Yoon-Koo, Prof
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 640 - 653
Summary Background Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | SUPPORTIVE CARE | WEEKLY PACLITAXEL | ONCOLOGY | 2ND-LINE CHEMOTHERAPY | IRINOTECAN | LEVEL | PLUS PACLITAXEL | HER2 | CANCER | DOCETAXEL | Follow-Up Studies | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Male | Stomach Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Aged, 80 and over | Adult | Female | Stomach Neoplasms - chemistry | Adenocarcinoma - chemistry | Taxoids - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Bridged-Ring Compounds - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Stomach Neoplasms - drug therapy | Maytansine - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Esophagogastric Junction | Gastrointestinal Hemorrhage - chemically induced | Retreatment | Intention to Treat Analysis | Bridged-Ring Compounds - adverse effects | Aged | Receptor, ErbB-2 - analysis | Trastuzumab | Adenocarcinoma | Medical research | Chemotherapy | Clinical trials | Medicine, Experimental | Metastasis | Esophageal cancer | Cancer | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
by Hatzis, Christos and Pusztai, Lajos and Valero, Vicente and Booser, Daniel J and Esserman, Laura and Lluch, Ana and Vidaurre, Tatiana and Holmes, Frankie and Souchon, Eduardo and Wang, Hongkun and Martin, Miguel and Cotrina, José and Gomez, Henry and Hubbard, Rebekah and Chacón, J. Ignacio and Ferrer-Lozano, Jaime and Dyer, Richard and Buxton, Meredith and Gong, Yun and Wu, Yun and Ibrahim, Nuhad and Andreopoulou, Eleni and Ueno, Naoto T and Hunt, Kelly and Yang, Wei and Nazario, Arlene and DeMichele, Angela and O’Shaughnessy, Joyce and Hortobagyi, Gabriel N and Symmans, W. Fraser
JAMA, ISSN 0098-7484, 05/2011, Volume 305, Issue 18, pp. 1873 - 1881
CONTEXT Prediction of high probability of survival from standard cancer treatments is fundamental for individualized cancer treatment strategies. OBJECTIVE To... 
MEDICINE, GENERAL & INTERNAL | ADJUVANT BREAST | NEOADJUVANT CHEMOTHERAPY | CYCLOPHOSPHAMIDE | SUBTYPES | DOXORUBICIN | GENE-EXPRESSION PROFILES | SENSITIVITY | CARCINOMA | PACLITAXEL | ACCURACY | Predictive Value of Tests | Prognosis | Prospective Studies | Oligonucleotide Array Sequence Analysis | Genomics | Humans | Middle Aged | Drug Resistance, Neoplasm | Risk | Gene Expression Profiling | Receptors, Estrogen - analysis | Taxoids - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Neoadjuvant Therapy | Genes, Neoplasm - genetics | Bridged-Ring Compounds - therapeutic use | Antineoplastic Agents, Hormonal - pharmacology | Neoplasm Recurrence, Local | Breast Neoplasms - drug therapy | Forecasting | Disease-Free Survival | Algorithms | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Genes, erbB-2 | Breast Neoplasms - mortality | Anthracyclines - therapeutic use | Biopsy, Needle | Neoadjuvant therapy | Anthracyclines | Patient outcomes | Breast cancer | Genetic aspects | Diagnosis | Drug therapy | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
by Eva S. Thomas and Henry L. Gomez and Rubi K. Li and Hyun-Cheol Chung and Luis E. Fein and Valorie F. Chan and Jacek Jassem and Xavier B. Pivot and Judith V. Klimovsky and Fernando Hurtado de Mendoza and Binghe Xu and Mario Campone and Guillermo L. Lerzo and Ronald A. Peck and Pralay Mukhopadhyay and Linda T. Vahdat and Henri H. Roché
Journal of Clinical Oncology, ISSN 0732-183X, 11/2007, Volume 25, Issue 33, pp. 5210 - 5217
Purpose Effective treatment options for patients with metastatic breast cancer resistant to anthracyclines and taxanes are limited. Ixabepilone has... 
RESISTANT | EPOTHILONE-B ANALOG | II CLINICAL-TRIAL | MULTICENTER | THERAPY | ONCOLOGY | BMS-247550 | PHASE-II | CHEMOTHERAPY | STANDARD | PACLITAXEL | Bridged-Ring Compounds - therapeutic use | Fluorouracil - analogs & derivatives | Capecitabine | Deoxycytidine - administration & dosage | Humans | Middle Aged | Breast Neoplasms - drug therapy | Epothilones - adverse effects | Disease Progression | Taxoids - therapeutic use | Neoplasm Metastasis | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Epothilones - administration & dosage | Adult | Breast Neoplasms - mortality | Deoxycytidine - adverse effects | Female | Aged | Anthracyclines - therapeutic use | Deoxycytidine - analogs & derivatives | Index Medicus | Anthracyclines | Antineoplastic Combined Chemotherapy Protocols | Breast Neoplasms | Life Sciences | Immunology | Taxoids | Bridged Compounds | Deoxycytidine | Epothilones | Fluorouracil
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Decline in the Use of Anthracyclines for Breast Cancer
by Sharon H. Giordano and Yu-Li Lin and Yong Fang Kuo and Gabriel N. Hortobagyi and James S. Goodwin
Journal of Clinical Oncology, ISSN 0732-183X, 06/2012, Volume 30, Issue 18, pp. 2232 - 2239
Purpose To determine the patterns of use of anthracycline- and taxane-based chemotherapy for breast cancer treatment. Methods Claims from a 5% national... 
ADJUVANT CHEMOTHERAPY | SURVIVAL | MEDICARE CLAIMS DATA | WOMEN | TRIAL COMPARING DOXORUBICIN | TRASTUZUMAB | ONCOLOGY | DOXORUBICIN PLUS CYCLOPHOSPHAMIDE | RANDOMIZED-TRIAL | HORMONAL-THERAPY | PACLITAXEL | Bridged-Ring Compounds - therapeutic use | Humans | Middle Aged | Breast Neoplasms - drug therapy | Taxoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Anthracyclines - therapeutic use | Chemotherapy, Adjuvant | Drug Utilization - statistics & numerical data | Index Medicus | Bc1 | Bc5 | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer
by Tolcher, A.W and Quinn, D.I and Ferrari, A and Ahmann, F and Giaccone, G and ke, T and Keating, A and Bono, de, J.S
Annals of Oncology, ISSN 0923-7534, 2012, Volume 23, Issue 4, pp. 968 - 973
Background: YM155, a small-molecule survivin suppressor, showed modest single-agent activity in a phase I study of heavily pretreated patients. This study was... 
Survivin | YM155 | Prostate cancer | Apoptosis | survivin | apoptosis | prostate cancer | ONCOLOGY | EXPRESSION | Bridged-Ring Compounds - therapeutic use | Taxoids - pharmacology | Humans | Imidazoles - adverse effects | Middle Aged | Naphthoquinones - therapeutic use | Drug Resistance, Neoplasm | Male | Naphthoquinones - pharmacology | Treatment Outcome | Antineoplastic Agents - therapeutic use | Imidazoles - pharmacology | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Taxoids - therapeutic use | Naphthoquinones - adverse effects | Inhibitor of Apoptosis Proteins - antagonists & inhibitors | Bridged-Ring Compounds - pharmacology | Aged, 80 and over | Prostatic Neoplasms - blood | Aged | Antineoplastic Agents - pharmacology | Imidazoles - therapeutic use | Prostatic Neoplasms - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients
by Jiralerspong, S and Kim, E. S and Dong, W and Feng, L and Hortobagyi, G. N and Giordano, S. H
Annals of Oncology, ISSN 0923-7534, 10/2013, Volume 24, Issue 10, pp. 2506 - 2514
Background To determine the relationship between obesity, diabetes, and survival in a large cohort of breast cancer patients receiving modern chemotherapy and... 
Survival outcomes | Body mass index | Obesity | Breast cancer | Prognosis | Diabetes | ADJUVANT CHEMOTHERAPY | METFORMIN | METAANALYSIS | body mass index | breast cancer | RISK | MELLITUS | survival outcomes | prognosis | TRIAL | MAMMOGRAPHY | WOMEN | ONCOLOGY | INFLAMMATION | BODY-MASS INDEX | diabetes | obesity | Body Composition | Body Mass Index | Bridged-Ring Compounds - therapeutic use | Receptors, Estrogen - metabolism | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Treatment Outcome | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Survival | Disease-Free Survival | Taxoids - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Diabetes Mellitus - epidemiology | Obesity - epidemiology | Tamoxifen - therapeutic use | Breast Neoplasms - mortality | Female | Anthracyclines - therapeutic use | Aromatase Inhibitors - therapeutic use | Cohort Studies | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
by Komrokji, Rami S and Seymour, John F and Roberts, Andrew W and Wadleigh, Martha and To, L. Bik and Scherber, Robyn and Turba, Elyce and Dorr, Andrew and Zhu, Joy and Wang, Lixia and Granston, Tanya and Campbell, Mary S and Mesa, Ruben A
Blood, ISSN 0006-4971, 04/2015, Volume 125, Issue 17, pp. 2649 - 2655
Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosine kinase 3 inhibitor that does not inhibit JAK1. It demonstrated a favorable... 
POLYCYTHEMIA-VERA | MYELOPROLIFERATIVE DISORDERS | NEOPLASMS | INTERNATIONAL-WORKING-GROUP | MUTATION | TYROSINE KINASE JAK2 | SCORING SYSTEM | HEMATOLOGY | MYELOID METAPLASIA | RUXOLITINIB | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Primary Myelofibrosis - drug therapy | Bridged-Ring Compounds - therapeutic use | Splenomegaly - drug therapy | Primary Myelofibrosis - complications | Humans | Middle Aged | Male | Spleen - drug effects | Primary Myelofibrosis - pathology | Splenomegaly - pathology | Splenomegaly - complications | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged, 80 and over | Adult | Bridged-Ring Compounds - adverse effects | Female | Aged | Spleen - pathology | Janus Kinase 2 - antagonists & inhibitors | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text The influence of obesity on survival in early, high-risk breast cancer: Results from the randomized SUCCESS A trial
by Widschwendter, Peter and Friedl, Thomas WP and Schwentner, Lukas and DeGregorio, Nikolaus and Jaeger, Bernadette and Schramm, Amelie and Bekes, Inga and Deniz, Miriam and Lato, Krisztian and Weissenbacher, Tobias and Kost, Bernd and Andergassen, Ulrich and Jueckstock, Julia and Neugebauer, Julia and Trapp, Elisabeth and Fasching, Peter A and Beckmann, Matthias W and Schneeweiss, Andreas and Schrader, Ines and Rack, Brigitte and Janni, Wolfgang and Scholz, Christoph
Breast Cancer Research, ISSN 1465-5411, 09/2015, Volume 17, Issue 1, pp. 129 - 129
Introduction: Obese breast cancer patients have worse prognosis than normal weight patients, but the level at which obesity is prognostically unfavorable is... 
BODY-MASS INDEX | POOLED ANALYSIS | EXPERIENCE | METAANALYSIS | ONCOLOGY | OVERWEIGHT | Body mass index | Anthracyclines | Breast cancer | Prognosis | Epidermal growth factor | Risk factors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors
by Dalvi, Maithili P and Wang, Lei and Zhong, Rui and Kollipara, Rahul K and Park, Hyunsil and Bayo, Juan and Yenerall, Paul and Zhou, Yunyun and Timmons, Brenda C and Rodriguez-Canales, Jaime and Behrens, Carmen and Mino, Barbara and Villalobos, Pamela and Parra, Edwin R and Suraokar, Milind and Pataer, Apar and Swisher, Stephen G and Kalhor, Neda and Bhanu, Natarajan V and Garcia, Benjamin A and Heymach, John V and Coombes, Kevin and Xie, Yang and Girard, Luc and Gazdar, Adi F and Kittler, Ralf and Wistuba, Ignacio I and Minna, John D and Martinez, Elisabeth D
Cell Reports, ISSN 2211-1247, 05/2017, Volume 19, Issue 8, pp. 1669 - 1684
Although non-small cell lung cancer (NSCLC) patients benefit from standard taxane-platin chemotherapy, many relapse, developing drug resistance. We established... 
lung cancer | histone methylation | taxane-platin chemotherapy | JIB-04 | GSK-J4 | KDM | histone demethylases | demethylase inhibitors | Jumonji demethylases | drug resistance | CELLS | MELANOMA | THERAPY | CHEMOTHERAPY REGIMENS | MECHANISM | GENE-EXPRESSION | LEUKEMIA | MULTIDRUG-RESISTANCE | CELL BIOLOGY | Lung Neoplasms - drug therapy | Transcription, Genetic - drug effects | Taxoids - pharmacology | Benzazepines - adverse effects | Humans | Aminopyridines - adverse effects | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Taxoids - therapeutic use | Hydrazones - adverse effects | Aminopyridines - therapeutic use | Carboplatin - therapeutic use | Hydrazones - therapeutic use | Jumonji Domain-Containing Histone Demethylases - antagonists & inhibitors | Bridged-Ring Compounds - pharmacology | Neoadjuvant Therapy | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Bridged-Ring Compounds - therapeutic use | Carcinoma, Non-Small-Cell Lung - genetics | Enzyme Inhibitors - pharmacology | Benzazepines - pharmacology | Pyrimidines - pharmacology | Enzyme Inhibitors - therapeutic use | Hydrazones - pharmacology | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Animals | Benzazepines - therapeutic use | Pyrimidines - therapeutic use | Aminopyridines - pharmacology | Pyrimidines - adverse effects | Cell Line, Tumor | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy | Histones - metabolism | Carboplatin - pharmacology | Methylation | Jumonji Domain-Containing Histone Demethylases - metabolism | Drug Resistance, Neoplasm - drug effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review
by Sciarra, Alessandro and Gentilucci, Alessandro and Silvestri, Ida and Salciccia, Stefano and Cattarino, Susanna and Scarpa, Susanna and Gatto, Antonio and Frantellizzi, Viviana and Von Heland, Magnus and Ricciuti, Gian Piero and Del Giudice, Francesco and Maggi, Martina
Medicine, ISSN 0025-7974, 05/2019, Volume 98, Issue 19, pp. e15608 - e15608
androgen receptor variant 7 (AR-V7) has been suggested as potential marker for treatment selection in men with metastatic castration-resistant prostate cancer... 
Bridged-Ring Compounds - therapeutic use | Phenylthiohydantoin - therapeutic use | Humans | Androstenes - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Phenylthiohydantoin - analogs & derivatives | Prostatic Neoplasms, Castration-Resistant - genetics | Genetic Variation | Taxoids - therapeutic use | Drug Resistance, Neoplasm - genetics | Receptors, Androgen - genetics | Biomarkers, Tumor - genetics | DEPRIVATION THERAPY | WHOLE-BLOOD | MEDICINE, GENERAL & INTERNAL | abiraterone | androgen receptor | CIRCULATING TUMOR-CELLS | MESSENGER-RNA | castration resistant | TREATMENT SELECTION | prostate neoplasm | taxane | enzalutamide | Medicine, Experimental | Medical research | Care and treatment | Prostate cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
by Hart, S and Goh, K.C and Novotny-Diermayr, V and Hu, C.Y and Hentze, H and Tan, Y.C and Madan, B and Amalini, C and Loh, Y.K and Ong, L.C and William, A.D and Lee, A and Poulsen, A and Jayaraman, R and Ong, K.H and Ethirajulu, K and Dymock, B.W and Wood, J.W
Leukemia, ISSN 0887-6924, 2011, Volume 25, Issue 11, pp. 1751 - 1759
SB1518 is an innovative pyrimidine-based macrocycle that shows a unique kinase profile with selective inhibition of Janus Kinase-2 (JAK2; IC50 = 23 and 19 nM... 
SB1518 | myelofibrosis | JAK2 | lymphoma kinase inhibitor | SUPPRESSOR | POLYCYTHEMIA-VERA | FREQUENT | EFFICACY | MYELOPROLIFERATIVE NEOPLASMS | KINASE INHIBITOR | POTENT | ONCOLOGY | MUTATIONS | LEUKEMIA | ABERRATIONS | HEMATOLOGY | Bridged-Ring Compounds - therapeutic use | Signal Transduction | Humans | Antineoplastic Agents - therapeutic use | Pyrimidines - pharmacology | Blotting, Western | Leukemia, Myeloid - drug therapy | Flow Cytometry | Leukemia, Lymphoid - drug therapy | Pyrimidines - therapeutic use | Bridged-Ring Compounds - pharmacology | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Cell Cycle - drug effects | Janus Kinase 2 - antagonists & inhibitors | Myelofibrosis | Physiological aspects | Drug targeting | Genetic aspects | Lymphomas | Research | Macrocycles | Drug therapy | Protein kinases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights